Mouse Anti-CSRNP1 Recombinant Antibody (CBXC-0594) (V2LY-0125-LY80)
Human chondrocytes were stimulated with IL-1 (0.05 ng/mL) in combination with OSM (10 ng/mL) for the indicated durations. Protein from either whole cell lysates (A) or subcellular fractions (C: a, cytosolic; b, membrane-bound; c, soluble nuclear; d, chromatin-bound; e, cytoskeletal) were resolved using SDS-PAGE and immunoblotted with an antibody to CSRNP1. Combined densitometric scans of separate blots for CSRNP1 in cell lysates (n = 3; B) or pooled soluble and chromatin-bound nuclear fractions (n = 5; D), relative to t = 0 h, are shown and were obtained from separate chondrocyte populations. ...View More
Human chondrocytes were treated with IL-1 (0.2 ng/mL) in combination with OSM (10 ng/mL) for 3 h. Nuclear lysates were prepared and subjected to either Western blotting alone (input) or DAPA with CSRNP1 or ATF3 antibodies, as described in the Materials and Methods. Non-biotinylated AP-1 oligonucleotides (50x excess; Comp) were used to confirm specificity of binding in the DAPAs. ...View More
Basic Information
| Application | Note |
| WB | 1:100-1:1,000 |
| IP | 1-2 μg per 100-500 μg of total protein (1 mL of cell lysate) |
Formulations & Storage [For reference only, actual COA shall prevail!]
Target
May have a tumor-suppressor function. May play a role in apoptosis.
Face morphogenesis Source: Ensembl
Platelet-derived growth factor receptor signaling pathway Source: Ensembl
Positive regulation of transcription by RNA polymerase II Source: UniProtKB
Post-embryonic development Source: Ensembl
Regulation of transcription by RNA polymerase II Source: GO_Central
Roof of mouth development Source: Ensembl
Skeletal system morphogenesis Source: Ensembl
Thrombocytopenia 6 (THC6):
A form of thrombocytopenia, a hematologic disorder defined by a decrease in the number of platelets in circulating blood, resulting in the potential for increased bleeding and decreased ability for clotting. THC6 is an autosomal dominant form. Affected individuals may also have bone abnormalities and an increased risk for myelofibrosis.
Dephosphorylated at Tyr-530 by PTPRJ (By similarity). Phosphorylated on Tyr-530 by c-Src kinase (CSK). The phosphorylated form is termed pp60c-src. Dephosphorylated by PTPRJ at Tyr-419. Normally maintained in an inactive conformation with the SH2 domain engaged with Tyr-530, the SH3 domain engaged with the SH2-kinase linker, and Tyr-419 dephosphorylated. Dephosphorylation of Tyr-530 as a result of protein tyrosine phosphatase (PTP) action disrupts the intramolecular interaction between the SH2 domain and Tyr-530, Tyr-419 can then become autophosphorylated, resulting in SRC activation. Phosphorylation of Tyr-530 by CSK allows this interaction to reform, resulting in SRC inactivation. CDK5-mediated phosphorylation at Ser-75 targets SRC to ubiquitin-dependent degradation and thus leads to cytoskeletal reorganization. Phosphorylated by PTK2/FAK1; this enhances kinase activity. Phosphorylated by PTK2B/PYK2; this enhances kinase activity. Upon activation of IL6ST by IL6, Tyr-419 is phosphorylated and Tyr-530 dephosphorylated (PubMed:25731159).
S-nitrosylation is important for activation of its kinase activity.
Ubiquitinated in response to CDK5-mediated phosphorylation. Ubiquitination mediated by CBLC requires SRC autophosphorylation at Tyr-419 and may lead to lysosomal degradation.
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon
Submit a review
Loading...
Please try the standard protocols which include: protocols, troubleshooting and guide.
Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols
Custom Antibody Labeling
We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).
Online InquiryContact us
